Company Filing History:
Years Active: 2023-2024
Title: Innovations by Inventor Markus Granzin
Introduction
Markus Granzin is an innovative inventor based in Germering, Germany. He has made significant contributions to the field of biotechnology and has been awarded two patents for his groundbreaking inventions.
Latest Patents
Among his latest patents is a remarkable method for NK cell transduction. This invention outlines an in-vitro procedure for transferring biological material into activated NK cells using a pseudotyped retroviral vector particle. The method involves the activation of NK cells followed by the introduction of a retroviral vector particle that incorporates a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein, which facilitates the transfer of biological material into the cells. A key aspect of this procedure is the use of an IL-1 family cytokine to effectively activate the NK cells.
Another noteworthy patent by Granzin details a chimeric antigen receptor (CAR) designed specifically for the BDCA2 antigen. This invention encompasses an engineered population of cells expressing the CAR, which is intended for use in the treatment of cancers expressing the BDCA2 antigen, such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). This advancement in CAR technology represents a significant step forward in targeted cancer therapy.
Career Highlights
Markus Granzin is currently associated with Miltenyi Biotec B.V. & Co. KG, a leading company in the field of biotechnology. His work there reflects his commitment to enhancing therapeutic options through innovative solutions in cell technology and immunotherapy.
Collaborations
Throughout his career, Granzin has collaborated with notable colleagues, including Rafijul Bari and Wing Leung. These partnerships highlight a strong collaborative spirit, which is essential in the rapidly evolving field of biomedical research and innovation.
Conclusion
In conclusion, Markus Granzin is a distinguished inventor whose contributions to the biotechnology industry have the potential to impact cancer treatment and cell therapy significantly. His patents underscore his innovative thinking and dedication to advancing medical science for better patient outcomes.